BioSpace reported on May 7 that biopharma job seekers saw more opportunities as the first quarter of 2026 progressed. While job postings on the BioSpace website dropped by 15% from January 2025 to January 2026, they increased year over year in February and March, with a rise of 5% and 7%, respectively. The quarter overall remained nearly flat compared to the previous year at +0.8%, but momentum appeared to build toward the end.
The report highlights two consecutive quarters of growth in live jobs, including an 8% increase in the first quarter of this year. This trend is seen as a positive sign for those hoping for an improved job market.
Mergers and acquisitions activity was strong during the period, with biopharma companies spending about $46.8 billion across nineteen acquisitions. Gilead Sciences led with its $7.8 billion acquisition of Arcellx. Initial public offerings also showed improvement; while only eight companies went public in all of last year, seven did so in just the first quarter of this year, including Generate:Biomedicines, whose IPO is expected to raise around $400 million.
Manufacturing employment prospects are growing as well. AbbVie, Eli Lilly, Genentech, Johnson & Johnson and Novartis announced plans to add nearly two thousand manufacturing jobs within several years at new facilities across the United States.
Opportunities for contract work have risen sharply according to BioSpace data; from March last year to March this year contract job postings increased by ninety-four percent while full-time roles rose five percent.
A recent U.S. Bureau of Labor Statistics report brought mixed news: In March, employers added one hundred seventy-eight thousand jobs—more than expected—but some gains were due to healthcare workers returning after strikes and better weather conditions improving hiring rates. The unemployment rate ticked down slightly from four point four percent in February to four point three percent in March; however long-term unemployment remains high both nationally and within biopharma based on a late-2025 survey informing BioSpace’s Employment Outlook report.
Layoffs slowed compared with last year's first quarter: thirty-five biopharmas cut or planned cuts versus seventy-four a year earlier according to BioSpace tallies through April sixth*. While affected headcount was higher (six thousand five hundred ninety-three) than last year's (five thousand nine hundred twenty-six), nearly half involved Viatris's restructuring which will occur gradually over three years rather than immediately impacting the market.
At a February webinar hosted by BioSpace titled “2026 Hiring Trends and Job Market Signals,” panelists expressed optimism about future employment opportunities in life sciences recruiting sectors. Leslie Loveless said: “They are conversations about real opportunities, and those jobs are opening, and so that is a wonderful place to be.”
*Layoff numbers exclude certain organizations such as contract development firms or medical device companies; data comes from press releases or regulatory filings where available.
